Featured Research

from universities, journals, and other organizations

Ashkenazi Ovarian Cancer Patients With BRCA Mutations Live Longer Than Those With Normal Gene

Date:
January 2, 2008
Source:
American Society of Clinical Oncology
Summary:
Israeli investigators have found that Ashkenazi Jewish women with ovarian cancer who have mutations in the BRCA1 or BRCA2 genes lived significantly longer than Ashkenazi Jewish ovarian cancer patients without these mutations. After up to nine years of follow-up, BRCA1/2 mutation carriers were 28 percent less likely to die from the disease, even though women with the BRCA mutations are significantly more likely to develop ovarian and breast cancers.

Israeli investigators have found that Ashkenazi Jewish women with ovarian cancer who have mutations in the BRCA1 or BRCA2 genes lived significantly longer than Ashkenazi Jewish ovarian cancer patients without these mutations. After up to nine years of follow-up, BRCA1/2 mutation carriers were 28 percent less likely to die from the disease, even though women with the BRCA mutations are significantly more likely to develop ovarian and breast cancers.

Related Articles


"These findings are encouraging news for BRCA mutation carriers," said Siegal Sadetzki, MD, MPH, head of the Cancer & Radiation Epidemiology Unit at the Gertner Institute, Chaim Sheba Medical Center in Tel Hashomer, Israel and the study's senior author. "It's possible that patients with these mutations respond better to chemotherapy -- hopefully, once we learn more about the mechanisms of this response, tailoring individual treatment will further improve survival."

Normal BRCA1/2 genes control cell growth. Mutations in these genes, which are more common among Ashkenazi Jewish women (Jewish women of Eastern European descent) than in the general population, increase the risk of breast and ovarian cancers.

In one of the largest studies of this topic to date, the researchers from the National Israeli Study of Ovarian Cancer compared five-year survival between 213 Ashkenazi ovarian cancer patients with BRCA1/2 mutations ("carriers") and 392 Ashkenazi ovarian cancer patients without the mutations ("non-carriers").

After five years, 46 percent of the carriers were still alive, compared with 34.4 percent of the non-carriers. Median survival was 53.7 months for carriers and 37.9 months for non-carriers. The differences in survival were most pronounced for women diagnosed with more advanced disease (stage III or IV), with five-year survival rates of 38.1 percent for carriers and 24.5 percent for non-carriers. These findings persisted after controlling for other factors that influence ovarian cancer survival, such as patient age and some biological features of the tumor.

The researchers also analyzed ovarian cancer survival according to whether women had a BRCA1 or a BRCA2 mutation. Women with BRCA1 mutations lived a median of 45.1 months, and women with BRCA2 mutations lived a median of 52.5 months.

The study is being published January 1 in the Journal of Clinical Oncology.

Journal article: "Effect of BRCA1/2 Mutations on Long-Term Survival of Invasive Ovarian Cancer." Angela Chetrit, et al, Gertner Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel.


Story Source:

The above story is based on materials provided by American Society of Clinical Oncology. Note: Materials may be edited for content and length.


Cite This Page:

American Society of Clinical Oncology. "Ashkenazi Ovarian Cancer Patients With BRCA Mutations Live Longer Than Those With Normal Gene." ScienceDaily. ScienceDaily, 2 January 2008. <www.sciencedaily.com/releases/2008/01/080101184644.htm>.
American Society of Clinical Oncology. (2008, January 2). Ashkenazi Ovarian Cancer Patients With BRCA Mutations Live Longer Than Those With Normal Gene. ScienceDaily. Retrieved March 28, 2015 from www.sciencedaily.com/releases/2008/01/080101184644.htm
American Society of Clinical Oncology. "Ashkenazi Ovarian Cancer Patients With BRCA Mutations Live Longer Than Those With Normal Gene." ScienceDaily. www.sciencedaily.com/releases/2008/01/080101184644.htm (accessed March 28, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, March 28, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) — The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins